CN1250221C - 女性性功能紊乱的治疗 - Google Patents

女性性功能紊乱的治疗 Download PDF

Info

Publication number
CN1250221C
CN1250221C CNB998044423A CN99804442A CN1250221C CN 1250221 C CN1250221 C CN 1250221C CN B998044423 A CNB998044423 A CN B998044423A CN 99804442 A CN99804442 A CN 99804442A CN 1250221 C CN1250221 C CN 1250221C
Authority
CN
China
Prior art keywords
apomorphine
blood flow
purposes
dosage form
vaginal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998044423A
Other languages
English (en)
Other versions
CN1313742A (zh
Inventor
R·埃尔-拉施戴
B·隆森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pentech Pharmaceuticals Inc
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of CN1313742A publication Critical patent/CN1313742A/zh
Application granted granted Critical
Publication of CN1250221C publication Critical patent/CN1250221C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

舌下给予脱水吗啡剂型能够改善人类女性性功能紊乱而没有明显的不需要的副作用。给予脱水吗啡可以增加神经刺激性阴蒂海绵体血流和阴道壁血流,以增强女性阴蒂勃起和阴道充血。优选维持脱水吗啡血浆浓度不高于约5.5ng/ml。

Description

女性性功能紊乱的治疗
发明领域
本发明涉及改善女性性功能紊乱的剂型和方法。更具体地说,本发明涉及含有脱水吗啡的组合物在改善女性性功能紊乱方面的用途。
发明背景
脱水吗啡是已经广泛用作催吐剂、镇静剂、抗帕金森氏病药物和行为改善剂的选择性多巴胺受体激动剂。最新研究和临床研究证实,脱水吗啡在男性具有表现为阴茎勃起的勃起作用。此前尚没有研究脱水吗啡对女性性功能的影响。
女性也可能发生随年龄而增加的并与存在心血管疾病高危因素和绝经有关的性功能紊乱。据认为引起男性阴茎勃起的某些血管和肌肉机制是女性生殖反应中的相似血管性因素。已知女性性觉醒(aroulsal)伴随使阴道充血和增加阴道润滑作用的动脉血流入;而且已知会阴肌肉有助于阴蒂勃起。
器质性或精神性因素或上述综合因素引起女性性功能紊乱。女性性功能紊乱包括不能达到或维持性兴奋的阴道润滑-肿胀反应直到性活动结束。已知器质性女性性功能紊乱与引起血流灌注不足、阴道充血不足和不完全阴蒂勃起的血管性障碍部分相关。
女性性功能紊乱不像男性性功能紊乱那样得到广泛研究。部分原因是获得志愿女性患者困难和历来认为女性性功能紊乱是性欲高潮(orgasmic)相关性的(性欲高潮延迟性的或非性欲高潮性的)或性欲性的,因此缺乏合适的动物模型。
已充分确立了New Zealand White雄性家兔用作阳萎动物模型的用途。最近研究报道了New Zealand White雌性家兔也是合适的较经济的研究女性性功能紊乱的血管病理学的动物模型,并且已经证明阴道充血和阴蒂勃起取决于血液灌注。参见例如Park等,“血管性女性性功能紊乱:阴道充血不足和阴蒂不完全勃起的血流动力学基础”,International Journal of Impotence Research,9,(1),27-37(1997年3月)。
在医学上治疗血管性性功能紊乱时,女性患者需要减轻性活动引起的不适或紊乱。对于精神性性功能紊乱的治疗而言,也可以使用有助于患者的精神性性治疗。
此前已证明脱水吗啡的口服生物利用度非常低。参见例如,Baldessarini等,述于Gessa等(编辑), Apomorphine and Other Dopaminomimetics,Basic Pharmacology1,219-228,Raven Press,N.Y.(1981)。
最近,关于男性的研究表明,只要实现明显勃起应答所需要的脱水吗啡的剂量不会伴随恶心和呕吐或其它严重的副作用如低动脉压、潮红和出汗,口服给予脱水吗啡可以用来诱导精神性男性阳痿患者的勃起。参见美国专利第5,624,677和E1-Rashidy等和Heaton等,Urology45,200-206(1995)。脱水吗啡在人类患者产生勃起反应的具体机制虽然不完全清楚,但是据认为是通过刺激大脑正中视叶前区中的多巴胺受体的中枢性作用。
现在已经发现某些脱水吗啡控释传递系统可以提供切实可行的改善女性性功能紊乱的治疗用途,同时减少副作用的可能性。
发明概述
给予脱水吗啡增强神经性刺激的阴蒂海绵体内血流和阴道壁血流,它们分别与增强女性阴蒂勃起和阴道充血有关。
通常含有约2-约12mg、优选约2-约8mg脱水吗啡的舌下脱水吗啡剂型可有效使女性产生性准备,而不会诱发明显恶心或其它不需要副作用。优选在性活动前15-20分钟舌下给予。维持脱水吗啡血浆浓度不高于约5.5ng/ml、优选约0.3-约4ng/ml、更优选约1-约2ng/ml,以在性活动期间维持足以维持性交期间的阴道充血、与其相关的阴道润滑和阴蒂勃起的脱水吗啡血液循环血清水平和中脑组织水平,但是低于诱发明显恶心的剂量。
图的简述
在附图中:
图1是图示安慰剂和每公斤体重的静脉内脱水吗啡量为0.05、0.1、0.2、0.3和0.4mg时,神经刺激前和后脱水吗啡对雌性家兔阴蒂血流(ml/分钟/100g组织)的影响的条形图;
图2是图示安慰剂和每公斤体重的静脉内脱水吗啡量为0.05、0.1、0.2、0.3和0.4mg时,神经刺激前和后脱水吗啡对雌性家兔阴道壁血流(ml/分钟/100g组织)的影响的条形图;和
图3是图示静脉内脱水吗啡对雌性家兔体循环动脉压(舒张压和收缩压)影响的图。
优选实施方案详述
脱水吗啡可以用下式表示:
并以游离碱形式或酸加成盐存在。对于本发明目的来说,优选脱水吗啡盐酸盐;然而,也可以用它的其它药学上可接受的部分。本文所用术语“脱水吗啡”包括游离碱型的该化合物或其药学上可接受的酸加成盐。除了所述盐酸盐外,其它可接受的酸加成盐包括氢溴酸盐、氢碘酸盐、硫酸氢盐、磷酸盐、酸式磷酸盐、乳酸盐、柠檬酸盐、酒石酸盐、水杨酸盐、琥珀酸盐、马来酸盐、葡萄糖酸盐等。
已知脱水吗啡当皮下给予约5mg剂量时是具有催吐剂用途的多巴胺激动剂。对于本发明目的,脱水吗啡或类似作用的多巴胺受体激动剂以足以兴奋患者中脑区细胞而仅具有最小副作用的剂量给予。据信该细胞兴奋作用是可能包括5-羟色胺和催产素有关的神经传导的级联刺激的部分。
从关于的男性的研究知道,可以刺激男性患者中脑区的多巴胺受体至足以通过舌下给予脱水吗啡以维持脱水吗啡血浆浓度不高于约5.5每毫升纳克(ng/ml)而引起勃起的程度。
根据在人类(帕金森氏病)和动物中进行的脱水吗啡盐酸盐研究的文献报道,脱水吗啡在女性和男性中的药代动力学相同。所以,已知剂量的脱水吗啡在男性中的作用发生及持续时间(类似于动物)也适用于女性。
在雌性家兔研究中发现脱水吗啡静脉内剂量每公斤约100微克(μg/kg)体重最适于对神经刺激阴道和阴蒂血流产生血管性作用。对于女性,与该剂量相关的最适剂量约为1/10或10μg/kg体重。在舌下含片剂型时,脱水吗啡的生物利用度约为皮下给予脱水吗啡盐酸盐的13%。假如女性平均体重约70公斤,脱水吗啡的有效性准备剂量约76μg/kg或约5.3mg片。因此,约2mg-约12mg的剂量范围将使女性产生性准备(即性刺激时阴蒂勃起和阴道充血)。
舌下给予优选在性活动前约2-约10分钟的时间范围或更长时间给予,优选约15分钟-约20分钟。在此时间范围内舌下给予的脱水吗啡剂量范围优选为约25μg/kg体重-约80μg/kg体重。
说明性优选的舌下给予剂型列于下表1中。
                            表1
150mg无水吗啡盐酸盐舌下含片
3-mg片剂
  脱水吗啡盐酸盐                             2.00%(重量)
  甘露醇                                     66.67%(重量)
  抗坏血酸                                   3.33%(重量)
  柠檬酸                                     2.00%(重量)
  Avicel PH102                               15.00%(重量)
  甲基纤维素Methocel E4M                     10.00%(重量)
  天冬甜素                                   0.67%(重量)
  硬脂酸镁                                   0.33%(重量)
4-mg片剂
  脱水吗啡盐酸盐                             2.66%(重量)
  甘露醇                                     66.00%(重量)
  抗坏血酸                                   3.33%(重量)
  柠檬酸                                     2.00%(重量)
  Avicel PH102                               15.00%(重量)
  甲基纤维素E4M                              10.00%(重量)
  天冬甜素                                   0.67%(重量)
  硬脂酸镁                                   0.33%(重量)
                                             %(重量)
5-mg片剂
  脱水吗啡盐酸盐                             3.33%(重量)
  甘露醇                                     65.34%(重量)
  抗坏血酸                                   3.33%(重量)
  柠檬酸                                     2.00%(重量)
  Avicel PH102                               15.00%(重量)
    甲基纤维素E4M                      10.00%(重量)
    天冬甜素                           0.67%(重量)
    硬脂酸镁                           0.33%(重量)
需要时以及为了促进吸收,并由此提高生物利用度,现在设计的剂型除了含有片剂赋形剂外还含有β-环糊精或β-环糊精衍生物如羟丙基-β-环糊精(HPBCD)。含有HPBCD的说明性剂型示于下表II和III。
                           表II
       含有羟丙基-β-环糊精的脱水吗啡盐酸盐舌下含片
                                        mg/片
           脱水吗啡盐酸盐               4.0
           HPBCD                        5.0
           抗坏血酸                     10.0
           PEG8000                      39.5
           甘露醇                       39.5
           天冬甜素                     2.0
                                  总计  100
                           表III
          含有β-环糊精的脱水吗啡盐酸盐舌下含片
                                        mg/片
        脱水吗啡盐酸盐                  5.0
        β-环糊精                       20.0
        抗坏血酸                        5.0
        甘露醇                          68.9
        硬脂酸镁                        1.0
        D&C 10号黄Aluminum Lake         0.1
                                  总计  100
以控制的溶出率传递脱水吗啡能够避免或延迟发生恶心,以便提供足以使阴道和阴蒂充血而不诱发恶心的脱水吗啡的循环血清水平和中脑组织水平。当脱水吗啡以或接近上述剂量范围的较高剂量给予时,通过同时给予神经节剂(神经节反应的抑制剂)如烟碱或盐酸山梗菜碱可以减少恶心发生的可能性。为此,脱水吗啡与神经节剂的重量比范围约10至约1。
其它可以与脱水吗啡联合使用的止吐剂有抗多巴胺剂如胃复安以及酚噻嗪类如氯丙嗪、甲哌氯丙嗪、哔哌吗嗪(pipamazine)、硫乙哌丙嗪、氮羟哌丙嗪盐酸盐等。此外,合适的止吐剂还有:5-羟色胺(5-HT)拮抗剂如多潘立酮、奥旦西隆(可市售获得其名称为Zofran的盐酸盐)等;组胺拮抗剂如盐酸氯苯丁嗪、盐酸苯甲嗪、茶苯海明等;副交感抑制剂如东莨菪碱等;以及其它止吐剂如甲磺哌丙嗪、三甲氧苯酰胺、苯奎胺盐酸盐、盐酸地芬尼多等。
含有烟碱的剂型和含有多潘立酮的剂型列于下表IV中。
                       表IV
          含有止吐剂的盐酸脱水吗啡舌下含片
                                       mg/片
        盐酸脱水吗啡                   5.0
        抗坏血酸                       5.0
        甘露醇                         67.9
        硬脂酸镁                       1.0
        烟碱                           1.0
        β-环糊精                      20.0
        D&C 10号黄Aluminum Lake        0.1
                              总计     100.0
                                      mg/片
        盐酸脱水吗啡                  5.0
        抗坏血酸                      5.0
        甘露醇                        58.9
        硬脂酸镁                      1.0
        多潘立酮                      10.0
        β-环糊精                     20.0
        D&C 10号黄Aluminum Lake       0.1
                              总计    100.0
优选的舌下含片剂型在至少约2分钟、但是优选低于约10分钟的时间范围内溶解。然而,需要的话溶出时间可以更长,只要能够维持必需的脱水吗啡血浆浓度。对于现在设计的剂型在水中的溶出时间更优选约3分钟至约5分钟。
以下实施例进一步采用合适的雌性动物模型说明脱水吗啡对雌性动物阴道和阴蒂血流的血管性作用。
方法
静脉内给予苯巴比妥麻醉New Zealand White雌性家兔(n=6,约3.5-4kg)。将20号血管导管植入右侧颈动脉内以测定体循环动脉压。进行腹部中线切口,解剖至阴道和阴蒂的盆神经分枝。用置于至阴道和阴蒂的盆神经分枝附近并连接至Grass SD-9刺激器的Harvard超小型电极进行神经刺激。用直接置入阴蒂海绵休组织和阴道壁内并连接至激光多普勒流量计的激光多普勒流量探针测量阴蒂海绵体和阴道壁血流。
刺激至阴道和阴蒂的盆神经分枝的前后分别记录基础动脉血压和阴蒂以及阴道壁血流。此后,以剂量反应方式(0.05mg/kg、0.1mg/kg、0.2mg/kg、0.3mg/kg和0.4mg/kg)经耳静脉给予脱水吗啡。神经刺激前后分别记录给予脱水吗啡对动脉血压和阴蒂以及阴道血流的影响。
结果
1.脱水吗啡对阴蒂海绵体内血流的影响
刺激至阴道和阴蒂的盆神经分枝引起阴蒂海绵体血流显著增加。静脉内给予脱水吗啡不会影响基础阴蒂海绵体内的血流。静脉内给予0.05mg/kg-0.2mg/kg浓度的脱水吗啡引起神经刺激诱发的阴蒂海绵体最大血流的增加并呈浓度依赖性,如图1所示。具体来说,与给予脱水吗啡前的观察到的结果相比,0.1mg/kg、0.2mg/kg和0.3mg/kg的脱水吗啡引起统计学上具有显著性的神经刺激诱发的阴蒂海绵体内最大血流的增加(图1)。
2.脱水吗啡对阴道壁血流的影响
静脉内给予脱水吗啡不会影响基础阴道壁血流。0.05mg/kg和0.2mg/kg浓度的脱水吗啡引起神经刺激诱发的阴道壁最大血流的增加并呈浓度依赖性,如图2所示。与给予脱水吗啡前的观察到的结果相比,静脉内给予0.1mg/kg和0.2mg/kg的脱水吗啡引起统计学上具有显著性的神经刺激诱发的阴道壁最大血流的增加(图1)。
0.4mg/kg浓度的脱水吗啡在神经刺激诱发的阴道壁血流增加时,产生副作用。
3.脱水吗啡对体循环动脉压的影响
脱水吗啡剂量增加对动脉舒张压的影响示于图3。静脉内给予脱水吗啡引起动脉舒张压浓度依赖性的中度降低,同时对动脉收缩压的影响最小。
结论
静脉内给予0.1mg/kg、0.2mg/kg和0.3mg/kg浓度的脱水吗啡引起神经刺激诱发的阴蒂海绵体最大血流的显著增加。静脉内给予0.1mg/kg和0.2mg/kg浓度的脱水吗啡引起阴道壁血流的显著增加。静脉内给予脱水吗啡所观察到的主要副作用是舒张压的中度降低。判定最适剂量为约0.1mg/kg。
采用雌性家兔动物模型进行的研究表明阴蒂勃起和阴道充血的血液动力学机制取决于阴蒂海绵体和阴道壁平滑肌的松弛作用。已知女性在性兴奋期间阴道血管充血必然伴有阴道润滑和外生殖器的肿胀。因此,脱水吗啡提高雌性家兔阴蒂血流被判定为增强人类女性阴蒂勃起的指标,而脱水吗啡提高阴道血流被判定为增强女性阴道润滑和增加阴道充血的指标。
已知盐酸脱水吗啡的剂量范围是种属依赖性的。人类有效剂量约为动物的1/10。因此,基于雌性家兔研究的静脉内给予的已知最适剂量约0.1mg/kg,与其相关的人类女性有效剂量应该约为0.01mg/kg。因为已知舌下给予脱水吗啡约为皮下给予脱水吗啡的13%生物利用度,所以约76μg/kg或约5.3mg片剂的剂量能够对70kg体重的女性产生显著的性准备(性刺激时产生阴蒂勃起和阴道充血)。所以,约2-约12mg、优选约2-约8mg、更优选约4-约6mg的剂量范围足以使女性产生性准备而不会诱发明显的恶心。
前述讨论和所报道的研究用来说明本发明而不是用来限制本发明。甚至在本发明精神以及范围内的其它变化仍是可能的且对本发明技术人员而言是显而易见的。

Claims (6)

1.脱水吗啡或其药学上可接受的酸加成盐在制备用于刺激人类女性中脑区的多巴胺受体的舌下药用剂型中的用途,所述剂型能改善所述女性性功能紊乱,引起阴蒂勃起和阴道充血的,其剂量足以使阴蒂内血流和阴道壁血流增加但是低于诱发明显恶心的量。
2.按照权利要求1的用途,其中所述剂型含有约2mg至约12mg脱水吗啡或其酸加成盐。
3.按照权利要求1的用途,其中酸加成盐是脱水吗啡盐酸盐。
4.按照权利要求1的用途,其中所述剂型包括β-环糊精或β-环糊精衍生物。
5.按照权利要求4的用途,其中所述β-环糊精衍生物为羟丙基-β-环糊精。
6.按照权利要求1的用途,其中所述剂型包括甘露醇和抗坏血酸作为赋形剂。
CNB998044423A 1998-01-30 1999-01-28 女性性功能紊乱的治疗 Expired - Fee Related CN1250221C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/016,252 US5945117A (en) 1998-01-30 1998-01-30 Treatment of female sexual dysfunction
US09/016252 1998-01-30

Publications (2)

Publication Number Publication Date
CN1313742A CN1313742A (zh) 2001-09-19
CN1250221C true CN1250221C (zh) 2006-04-12

Family

ID=21776169

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998044423A Expired - Fee Related CN1250221C (zh) 1998-01-30 1999-01-28 女性性功能紊乱的治疗

Country Status (34)

Country Link
US (2) US5945117A (zh)
EP (1) EP1056419A4 (zh)
JP (1) JP2002501875A (zh)
KR (1) KR20010040477A (zh)
CN (1) CN1250221C (zh)
AR (1) AR017976A1 (zh)
AU (1) AU752928B2 (zh)
BG (1) BG64667B1 (zh)
BR (1) BR9908038A (zh)
CA (1) CA2322289A1 (zh)
CO (1) CO4970819A1 (zh)
CR (1) CR5959A (zh)
DZ (1) DZ2714A1 (zh)
GC (1) GC0000096A (zh)
GT (1) GT199900013A (zh)
HK (1) HK1040901B (zh)
HN (1) HN1999000015A (zh)
HU (1) HUP0101268A3 (zh)
IL (2) IL137569A0 (zh)
JO (1) JO2085B1 (zh)
MA (1) MA26600A1 (zh)
MX (1) MXPA00007447A (zh)
NO (1) NO319821B1 (zh)
NZ (1) NZ506597A (zh)
PA (1) PA8467801A1 (zh)
PE (1) PE20000240A1 (zh)
PL (1) PL194350B1 (zh)
SK (1) SK11362000A3 (zh)
TN (1) TNSN99008A1 (zh)
TR (1) TR200002220T2 (zh)
TW (1) TW550069B (zh)
UY (1) UY25374A1 (zh)
WO (1) WO1999038467A1 (zh)
ZA (1) ZA99686B (zh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
JP2002518435A (ja) * 1998-06-22 2002-06-25 クイーンズ ユニバーシティ アット キングストン 女性の性機能不全の治療または改善のための方法および組成物
US20050245494A1 (en) * 1999-07-01 2005-11-03 40 J's Llc Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
EP1284735A4 (en) 2000-04-07 2006-01-11 Tap Pharmaceutical Prod Inc APOMORPHINE DERIVATIVES AND METHODS OF USE
CA2408399A1 (en) 2000-05-09 2001-11-15 Nitromed, Inc. Infrared thermography and methods of use
WO2002000240A2 (en) 2000-06-27 2002-01-03 Qualilife Pharmaceuticals Inc. Compositions and methods for treating females sexual response
US6852323B2 (en) 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
CA2429047A1 (en) 2000-11-15 2002-05-23 Tap Pharmaceutical Products, Inc. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
WO2002041894A2 (en) * 2000-11-22 2002-05-30 Abbott Laboratories Selective dopamine d4 receptor agonists for treating sexual dysfunction
BR0207024A (pt) * 2001-02-08 2004-02-25 Pharmacia Corp Global Patent D Medicamento com ação inicial rápida para o tratamento de disfunção sexual
BR0308567A (pt) * 2002-03-19 2007-01-09 Michael Holick derivados de glicosìdeo e glicosìdeo de ortoéster de apomorfina, análogos, e seus usos
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
US20040138291A1 (en) * 2002-10-10 2004-07-15 Adams Michael A. Treatment of sexual dysfunction
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
BRPI0409380A (pt) * 2003-04-14 2006-04-18 Vectura Ltd composições farmacêuticas
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
GB0314054D0 (en) * 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
GEP20084550B (en) * 2004-04-30 2008-11-25 Warner Lambert Co Substituted morpholine compounds for the treatment of central nervous system disorders
WO2006100588A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
DE602006003416D1 (de) * 2005-03-21 2008-12-11 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
WO2006105615A1 (en) * 2005-04-08 2006-10-12 Ozpharma Pty Ltd Buccal delivery system
EP1917257A1 (en) * 2005-08-10 2008-05-07 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
WO2007110868A2 (en) 2006-03-28 2007-10-04 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US7800094B2 (en) * 2007-06-11 2010-09-21 Macronix International Co., Ltd. Resistance memory with tungsten compound and manufacturing
EA025054B1 (ru) 2009-06-12 2016-11-30 Сайнэпсус Терапьютикс, Инк. Единичная дозированная форма для сублингвального введения, включающая частицы апоморфина, для лечения болезни паркинсона или половой дисфункции
US20130210867A1 (en) * 2010-04-15 2013-08-15 Life Science Enhancement Corporation Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction
KR101890317B1 (ko) 2010-12-16 2018-08-22 선오비온 파마슈티컬스 인코포레이티드 설하 필름
WO2012140642A1 (en) 2011-04-10 2012-10-18 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
EP3285771A4 (en) 2015-04-21 2018-12-05 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
AU4312593A (en) * 1992-05-18 1993-12-13 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and Parkinson's disease
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
EP0758895B1 (en) * 1994-04-22 2000-01-26 Pentech Pharmaceuticals, Inc. Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
GT199900013A (es) 2001-07-20
TR200002220T2 (tr) 2000-12-21
IL137569A (en) 2006-08-01
NO20003845L (no) 2000-09-28
DZ2714A1 (fr) 2003-09-01
BR9908038A (pt) 2002-01-02
TNSN99008A1 (fr) 2005-11-10
NO20003845D0 (no) 2000-07-27
CO4970819A1 (es) 2000-11-07
GC0000096A (en) 2005-06-29
WO1999038467A1 (en) 1999-08-05
NZ506597A (en) 2003-07-25
HUP0101268A3 (en) 2002-12-28
JO2085B1 (en) 2000-05-21
CN1313742A (zh) 2001-09-19
CR5959A (es) 1999-07-28
MXPA00007447A (es) 2006-01-25
SK11362000A3 (sk) 2001-02-12
TW550069B (en) 2003-09-01
HN1999000015A (es) 1999-08-23
CA2322289A1 (en) 1999-08-05
UY25374A1 (es) 1999-09-27
AR017976A1 (es) 2001-10-24
EP1056419A4 (en) 2007-05-02
PE20000240A1 (es) 2000-03-31
NO319821B1 (no) 2005-09-19
HK1040901A1 (en) 2002-06-28
KR20010040477A (ko) 2001-05-15
EP1056419A1 (en) 2000-12-06
AU752928B2 (en) 2002-10-03
MA26600A1 (fr) 2004-12-20
PL194350B1 (pl) 2007-05-31
ZA99686B (en) 1999-07-28
JP2002501875A (ja) 2002-01-22
US5945117A (en) 1999-08-31
HUP0101268A2 (hu) 2001-09-28
PA8467801A1 (es) 2000-09-29
IL137569A0 (en) 2001-07-24
AU2564499A (en) 1999-08-16
HK1040901B (zh) 2006-11-24
BG104715A (bg) 2001-02-28
PL342062A1 (en) 2001-05-21
US6193992B1 (en) 2001-02-27
BG64667B1 (bg) 2005-11-30

Similar Documents

Publication Publication Date Title
CN1250221C (zh) 女性性功能紊乱的治疗
CN1338939A (zh) 治疗雄性勃起障碍的组合物
CN1103589C (zh) 调节人体性反应的方法
US6395744B1 (en) Method and compositions for the treatment or amelioration of female sexual dysfunction
ES2244418T3 (es) Composiciones de apomorfina y sidenalfilo y utilizacion de los mismos para el tratamiento de la disfuncion erectil.
CN1498104A (zh) 肽类化合物用于治疗异常性疼痛或其他不同类慢性痛或幻痛的新应用
US20060281752A1 (en) Method for the normalization of sexual response and amelioration of long term genital tissue degradation
CN1335772A (zh) 阿扑吗啡在制备治疗男性器质性勃起障碍的药物中的应用
AU5040500A (en) Compositions and methods comprising morphine gluconate
CN1471395A (zh) 阿扑吗啡衍生物及其使用方法
EP0996447B1 (en) Combination therapy for modulating the human sexual response
CN1315177A (zh) 用特定血浆浓度水平的阿朴吗啡治疗性功能障碍的方法
WO2002024202A1 (en) Nasal delivery of apomorphine in combination with glycol derivatives
CN1610548A (zh) 依贝沙坦在制备用来预防或治疗肺动脉高压的药物中的应用
JP2002338471A (ja) 勃起機能不全のための治療薬
CN1407892A (zh) 间歇性跛行治疗药
AU2003204720B2 (en) Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
CZ20002755A3 (cs) Způsob zlepšení ženské sexuální dysfunkce
AU2005201509A1 (en) Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee